Helicobacter pylori eradication improves glycemic control in type 2 diabetes patients with asymptomatic active Helicobacter pylori infection

研究成果: Article

2 引文 (Scopus)

摘要

Aims/Introduction: Helicobacter pylori infection is associated with insulin resistance and glycemia in non-diabetes. However, the relationship between H. pylori infection and glycemia in diabetes remains inconclusive. Therefore, we explored the effect of H. pylori infection status and its eradication on glycemic control and antidiabetic therapy in type 2 diabetes patients. Materials and Methods: A total of 549 diabetes patients were recruited for sequential two-step approach (immunoglobulin G [IgG] serology followed by 13C-urea breath test [UBT]) to discriminate “active” (IgG+ and UBT+) from “non-active” (UBT− or IgG−) H. pylori infection, and “past” (IgG+ but UBT−) from “never/remote” (IgG−) infection. The differences in hemoglobin A1c (A1C) and antidiabetic regimens between groups were compared. In the “active” infection group, the differences in A1C changes between participants with and without 10-day eradication therapy were compared after 3 months. Results: Despite no between-group difference in A1C, the “active” infection group (n = 208) had significantly more prescriptions of oral antidiabetic drug classes (2.1 ± 1.1 vs 1.8 ± 1.1, P = 0.004) and higher percentages of sulfonylurea use (67.3% vs 50.4%, P < 0.001) than the “non-active” infection group (n = 341). There were no differences in A1C and oral antidiabetic drug classes between “past” (n = 111) and “never/remote” infection groups (n = 230). Compared with the non-eradication group (n = 99), the eradication group (n = 98) had significant within-group (−0.17 ± 0.80%, P = 0.036) and between-group (−0.23 ± 0.10%, P = 0.024) improvements in A1C. Conclusions: Diabetes patients with active H. pylori infection need higher glycemic treatment intensity to achieve comparable glycemia. Furthermore, H. pylori eradication decreases A1C, and thus improves glycemic control.

原文English
頁(從 - 到)1092-1101
頁數10
期刊Journal of Diabetes Investigation
10
發行號4
DOIs
出版狀態Published - 2019 七月

指紋

Helicobacter Infections
Helicobacter pylori
Pylorus
Breath Tests
Infection
Hypoglycemic Agents
Urea
Serology
Prescriptions
Insulin Resistance
Hemoglobins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

引用此文

@article{aa5ca07c74ff427ba02abd21a5a9178e,
title = "Helicobacter pylori eradication improves glycemic control in type 2 diabetes patients with asymptomatic active Helicobacter pylori infection",
abstract = "Aims/Introduction: Helicobacter pylori infection is associated with insulin resistance and glycemia in non-diabetes. However, the relationship between H. pylori infection and glycemia in diabetes remains inconclusive. Therefore, we explored the effect of H. pylori infection status and its eradication on glycemic control and antidiabetic therapy in type 2 diabetes patients. Materials and Methods: A total of 549 diabetes patients were recruited for sequential two-step approach (immunoglobulin G [IgG] serology followed by 13C-urea breath test [UBT]) to discriminate “active” (IgG+ and UBT+) from “non-active” (UBT− or IgG−) H. pylori infection, and “past” (IgG+ but UBT−) from “never/remote” (IgG−) infection. The differences in hemoglobin A1c (A1C) and antidiabetic regimens between groups were compared. In the “active” infection group, the differences in A1C changes between participants with and without 10-day eradication therapy were compared after 3 months. Results: Despite no between-group difference in A1C, the “active” infection group (n = 208) had significantly more prescriptions of oral antidiabetic drug classes (2.1 ± 1.1 vs 1.8 ± 1.1, P = 0.004) and higher percentages of sulfonylurea use (67.3{\%} vs 50.4{\%}, P < 0.001) than the “non-active” infection group (n = 341). There were no differences in A1C and oral antidiabetic drug classes between “past” (n = 111) and “never/remote” infection groups (n = 230). Compared with the non-eradication group (n = 99), the eradication group (n = 98) had significant within-group (−0.17 ± 0.80{\%}, P = 0.036) and between-group (−0.23 ± 0.10{\%}, P = 0.024) improvements in A1C. Conclusions: Diabetes patients with active H. pylori infection need higher glycemic treatment intensity to achieve comparable glycemia. Furthermore, H. pylori eradication decreases A1C, and thus improves glycemic control.",
author = "Cheng, {Kai Pi} and Yang, {Yao Jong} and Hung, {Hao Chang} and Lin, {Ching Han} and Wu, {Chung Tai} and Hung, {Mei Hui} and Sheu, {Bor Shyang} and Ou, {Horng Yih}",
year = "2019",
month = "7",
doi = "10.1111/jdi.12991",
language = "English",
volume = "10",
pages = "1092--1101",
journal = "Journal of Diabetes Investigation",
issn = "2040-1116",
publisher = "Blackwell Publishing Asia Pty Ltd",
number = "4",

}

TY - JOUR

T1 - Helicobacter pylori eradication improves glycemic control in type 2 diabetes patients with asymptomatic active Helicobacter pylori infection

AU - Cheng, Kai Pi

AU - Yang, Yao Jong

AU - Hung, Hao Chang

AU - Lin, Ching Han

AU - Wu, Chung Tai

AU - Hung, Mei Hui

AU - Sheu, Bor Shyang

AU - Ou, Horng Yih

PY - 2019/7

Y1 - 2019/7

N2 - Aims/Introduction: Helicobacter pylori infection is associated with insulin resistance and glycemia in non-diabetes. However, the relationship between H. pylori infection and glycemia in diabetes remains inconclusive. Therefore, we explored the effect of H. pylori infection status and its eradication on glycemic control and antidiabetic therapy in type 2 diabetes patients. Materials and Methods: A total of 549 diabetes patients were recruited for sequential two-step approach (immunoglobulin G [IgG] serology followed by 13C-urea breath test [UBT]) to discriminate “active” (IgG+ and UBT+) from “non-active” (UBT− or IgG−) H. pylori infection, and “past” (IgG+ but UBT−) from “never/remote” (IgG−) infection. The differences in hemoglobin A1c (A1C) and antidiabetic regimens between groups were compared. In the “active” infection group, the differences in A1C changes between participants with and without 10-day eradication therapy were compared after 3 months. Results: Despite no between-group difference in A1C, the “active” infection group (n = 208) had significantly more prescriptions of oral antidiabetic drug classes (2.1 ± 1.1 vs 1.8 ± 1.1, P = 0.004) and higher percentages of sulfonylurea use (67.3% vs 50.4%, P < 0.001) than the “non-active” infection group (n = 341). There were no differences in A1C and oral antidiabetic drug classes between “past” (n = 111) and “never/remote” infection groups (n = 230). Compared with the non-eradication group (n = 99), the eradication group (n = 98) had significant within-group (−0.17 ± 0.80%, P = 0.036) and between-group (−0.23 ± 0.10%, P = 0.024) improvements in A1C. Conclusions: Diabetes patients with active H. pylori infection need higher glycemic treatment intensity to achieve comparable glycemia. Furthermore, H. pylori eradication decreases A1C, and thus improves glycemic control.

AB - Aims/Introduction: Helicobacter pylori infection is associated with insulin resistance and glycemia in non-diabetes. However, the relationship between H. pylori infection and glycemia in diabetes remains inconclusive. Therefore, we explored the effect of H. pylori infection status and its eradication on glycemic control and antidiabetic therapy in type 2 diabetes patients. Materials and Methods: A total of 549 diabetes patients were recruited for sequential two-step approach (immunoglobulin G [IgG] serology followed by 13C-urea breath test [UBT]) to discriminate “active” (IgG+ and UBT+) from “non-active” (UBT− or IgG−) H. pylori infection, and “past” (IgG+ but UBT−) from “never/remote” (IgG−) infection. The differences in hemoglobin A1c (A1C) and antidiabetic regimens between groups were compared. In the “active” infection group, the differences in A1C changes between participants with and without 10-day eradication therapy were compared after 3 months. Results: Despite no between-group difference in A1C, the “active” infection group (n = 208) had significantly more prescriptions of oral antidiabetic drug classes (2.1 ± 1.1 vs 1.8 ± 1.1, P = 0.004) and higher percentages of sulfonylurea use (67.3% vs 50.4%, P < 0.001) than the “non-active” infection group (n = 341). There were no differences in A1C and oral antidiabetic drug classes between “past” (n = 111) and “never/remote” infection groups (n = 230). Compared with the non-eradication group (n = 99), the eradication group (n = 98) had significant within-group (−0.17 ± 0.80%, P = 0.036) and between-group (−0.23 ± 0.10%, P = 0.024) improvements in A1C. Conclusions: Diabetes patients with active H. pylori infection need higher glycemic treatment intensity to achieve comparable glycemia. Furthermore, H. pylori eradication decreases A1C, and thus improves glycemic control.

UR - http://www.scopus.com/inward/record.url?scp=85064534585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064534585&partnerID=8YFLogxK

U2 - 10.1111/jdi.12991

DO - 10.1111/jdi.12991

M3 - Article

C2 - 30556347

AN - SCOPUS:85064534585

VL - 10

SP - 1092

EP - 1101

JO - Journal of Diabetes Investigation

JF - Journal of Diabetes Investigation

SN - 2040-1116

IS - 4

ER -